The use of dexmedetomidine (DEX) has been extended in preterm newborns, but the effects on cerebral activity and their relationship with haemodynamic changes has not been studied.
We retrospectively studied the effects of DEX administered to 10 preterm newborns, assessing amplitude-integrated EEG (aEEG) parameters, brain regional SO2 (brSO2), heart rate, non-invasive mean blood pressure (MBP), transcutaneous oxygen saturation (SpO2), venous pCO2 and haemoglobin (Hb) values, in two 6-hour periods: one starting 6 hours before the beginning of DEX perfusion and the other 6 hours afterwards.
DEX infusion led to brSO2 decrease not associated to heart rate, MBP, SpO2, Hb or pCO2 variation, which suggests that brSO2 decrease could be related to local vasoconstriction. DEX infusion led to prolongation of interburst interval and reduction of cycling. Such effects, not been described so far, should be considered in the assessment of aEEG traces after DEX administration to avoid misinterpretations regarding patient’s prognosis. More studies are needed to assess the safety of DEX use in the newborn.
- Intensive Care Units, Paediatric
- Intensive Care Units, Neonatal
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
What is already known on this topic?
Dexmedetomidine is an effective sedative agent which is increasingly used in preterm newborns with no severe side effects reported so far.
However, there are no studies on the effects of dexmedetomidine on cerebral activity in preterm newborns.
What this study adds?
Dexmedetomidine infusion to preterm newborns decreases amplitude-integrated electroencephalogram activity and brain oxygenation.
Such effects should be considered to avoid misinterpretations regarding the patient’s prognosis.
Dexmedetomidine (DEX) is an effective alternative to benzodiazepines increasingly used to provide sedation in newborn babies because of the lack of short-term severe side effects other than moderate hypotensive effects.1 Lately, its use has been extended to preterm newborns, with no reported severe side effects to date.1 However, there are no studies on the effects of DEX on cerebral activity in preterm newborns, in contrast with other sedoanalgesic drugs2 such as morphine and propofol. Awareness on the effects of sedative drugs on preterm newborn brain activity is important to avoid misinterpretations about the prognosis of those patients. The aim of this study was to determine how DEX affects cerebral activity in preterm infants and whether those effects would be related to DEX-induced haemodynamic changes.
Informed consent exemption was approved due to the retrospective nature of the study.
All very low birthweight infants (VLBWI) born between January 2019 and May 2021 receiving DEX during their stay in our neonatal intensive care unit, were retrospectively studied collecting data from the medical charts and amplitude-integrated EEG (aEEG) (Olympic Brain Monitor, Natus, California, USA) recordings using neonatal sensors (Ambu Neuroline 715, Ambu, Denmark). DEX was selected as the first-line sedative except in four babies who needed deeper sedoanalgesia because of their clinical condition; in these latter babies fentanyl was selected as the first-line sedative and DEX was added when satisfactory sedation was not achieved with fentanyl alone. Two 6-hour periods were studied: one just before and the other starting 6 hours after DEX infusion (0.1–0.4 µg/kg/min). aEEG trace was assessed by a researcher blind to the corresponding period. The following parameters were recorded hourly: aEEG (lower limit amplitude in µV, interburst interval (IBI) and cycling (quantified after Burjdalov Score)); brain regional SO2 (brSO2) using near-infrared spectroscopy (INVOS 5100C, Medtronics, Colorado, USA) (percentage of baseline value) with neonatal sensors; non-invasive mean blood pressure (MBP) and heart rate, transcutaneous oxygen saturation (SpO2) (Masimo Radical-7), venous pCO2 and haemoglobin (Hb). Fractional tissue oxygen extraction (FTOE) was calculated using SpO2 and brSO2 values: (SpO2 − brSO2)/SpO2.
Exclusion criteria were severe intraventricular haemorrhage or periventricular leucomalacia or non-interpretable aEEG trace because of artefacts, but no newborn met such criteria.
Median (95% CI) of each parameter in each period of study was calculated. Since data were not normally distributed (Shapiro-Wilkins test), changes before and after DEX infusion were studied using the Wilcoxon test. Correlations between parameters (Spearman’s linear regression) and contingency 2×2 tables (Fisher’s exact test) were also studied. A value of p<0.05 was considered statistically significant. Data were analysed using SPSS software (V.25.0; IBM, New York, USA).
Ten patients fulfilled the inclusion criteria over the study period. General data are summarised in table 1.
DEX infusion led to brSO2 decrease (75 (68–80.5) vs 67.7 (58.5–77)%, W=−52, p=0.005) and FTOE increase (0.20 (0.11–0.27) vs 0.28 (0.19–0.37)%, W=64, p=0.002) but did not modify heart rate (160.8 (152.5–171.5) vs 153.6 (136.5–169)%, W=−24, p=0.24), MBP (39.6 (35–45) vs 39.5 (28–47)%, W=4, p=0.84), SpO2 (93.5 (91.9–94.3) vs 93.0 (91.9–94.6)%, W=5, p=0.82), Hb (10.6 (9.7–13.3) vs 12.1 (10.2–13.4),W=5, p=0.81) or pCO2 (42 (40–63) vs 51 (42–56), W=5, p=0.73).
DEX infusion did not modify the lower aEEG amplitude limit (W=−16, p=0.30; variance = 1.7 vs 3.3, coefficient of variation 0.34 vs 0.59 for basal and DEX, respectively) but led to prolongation of IBI (W=55, p=0.002; variance = 17.5 vs 29.73, coefficient of variation 0.30 vs 0.42 for basal and DEX, respectively) and reduction of cycling (W=−45, p=0.03; variance = 2.4 vs 1.6, coefficient of variation 0.90 vs 3.1 for basal and DEX, respectively) (figure 1). Cycling was present in seven babies before and in only one after DEX (p=0.01). brSO2 did not correlate with IBI (R2=0.01, F=0.08, p=0.78) or cycling (R2=0.01, F=0.14, p=0.72).
In this study DEX infusion modified brain activity in VLBWI as assessed by aEEG, which led to the prolongation of IBI and the disappearance of cycling. These two parameters are of major prognostic value regarding neurological outcome in premature neonates.3 Therefore, awareness about such an effect of DEX is important to avoid misinterpretations about the patient’s clinical condition. Changes in the aEEG pattern and background have been reported in preterm neonates for propofol as well as benzodiazepines and opioids2 but not for DEX to date.
DEX infusion neither induced bradycardia or hypotension nor SpO2, pCO2 or Hb decrease in our patients. Therefore, DEX-induced decrease of brSO2 and rise of FTOE could not be attributed to systemic hypotension, hypoxia, anaemia or hypocapnia as it could not be attributed to increased brain activity. It can be speculated, therefore, that DEX-induced brSO2 decrease might reflect the vasoconstrictor effect reported for DEX in cerebral vessels.4 In fact, sedative infusion usually leads to increased brSO2 because of reduced brain activity.5 Reduction of brSO2 is a noteworthy effect although it had no relationship with the prolongation of IBI or the disappearance of cycling.
The fact that such alterations of aEEG and brSO2 were also observed in those newborns already receiving fentanyl supports the consistency of DEX effects on cerebral activity, although some additive effects of DEX and other sedatives cannot be ruled out in our study. However, since this is a small size retrospective study, larger prospective studies are warranted to confirm DEX effects on brain activity and cerebral blood flow and to analyse gestational age, sex and DEX dose influences on those effects.
In conclusion, DEX infusion to ELBWI led to decreased brain activity with prolonged IBI and cycling disappearance, and decreased brSO2. Such effects should be considered to avoid misinterpretations regarding the patient’s prognosis. More studies are needed to assess the safety of DEX use in the newborn.
Patient consent for publication
This study involves human participants and was approved by Comité ético de investigación del Hospital Clínico San Carlos (ID 20/772-E). Informed consent exemption was approved due to the retrospective nature of the study.
Contributors CL conceptualised and designed the study, collected data, carried out the initial analyses and drafted the initial manuscript. SV and LA designed the data collection instruments, collected data and revised the manuscript. MO conceptualised and designed the study, coordinated and supervised data collection, and critically reviewed the manuscript for important intellectual content.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.